Camrelizumab plus rivoceranib delivered a median overall survival of 23.8 months versus 15.2 months on sorafenib in first-line unresectable hepatocellular carcinoma (HR 0.64; one-sided p<0.0001). Median progression-free survival was 5.6 versus 3.7 months (HR 0.54; one-sided p<0.0001). Grade 3/4 treatment-related adverse events were led by hypertension (39% vs 15%) and elevated AST/ALT (17%/14% vs 5%/3%); serious treatment-related adverse events occurred in 25% vs 7% of patients. The trial enrolled 543 patients across 95 sites in 13 countries; 83% were Asian and 84% male. Elevar Therapeutics’ final analysis of the Phase 3 CARES-310 study is now published in The Lancet Oncology, and the company plans to resubmit a U.S. NDA for the camrelizumab/rivoceranib combination in January 2026. The open-label, international study compared the PD-1 inhibitor plus VEGFR TKI against sorafenib in the first-line uHCC setting. The regimen is already approved in China; Elevar holds rights to rivoceranib ex-China and has licensed camrelizumab commercialization rights in most territories outside Greater China and Korea. Strategically, Elevar is trying to convert mature OS and a peer-reviewed dataset into a second run at U.S. approval in a crowded frontline HCC market defined by immunotherapy plus anti-angiogenic backbones. The efficacy signal is competitive on headline OS, but the control choice exposes a known regulatory tension: sorafenib is no longer the dominant U.S. standard, with atezolizumab/bevacizumab and durvalumab/tremelimumab embedded as preferred regimens. That raises the bar for establishing clinical relevance via cross-trial context, subgroup robustness, and potentially supplemental analyses. The demographic concentration in Asia—a reflection of global HCC epidemiology—adds another layer, as regulators continue to scrutinize generalizability, regional practice patterns, and HBV-heavy populations when extrapolating to U.S. care. For sponsors and CROs, the case underscores ongoing pressure to anchor pivotal oncology trials to contemporaneous, regionally relevant comparators if U.S. approval is a goal. It also reinforces the operational cost of late control shifts: when SOC moves during enrollment, programs that stay with legacy comparators may face additional evidentiary demands later. Sites should note the safety and monitoring profile if the regimen reaches the U.S. market: high rates of grade 3/4 hypertension and liver enzyme elevations imply tighter blood pressure control, more frequent labs, and earlier intervention protocols, all of which affect clinic flow and supportive care planning. For regulators and guidelines bodies, the question will be where a PD-1/TKI doublet slots relative to the established antibody/VEGF and dual‑IO options, and whether patient subsets—by etiology, geography, or bleeding risk—justify differentiated positioning. Next, watch for the content of Elevar’s resubmission: the extent of U.S.-focused analyses, external or historical control methodologies, and any commitments to postmarketing studies that benchmark against current SOC will be telling. An advisory committee is plausible given comparator and population considerations. Commercial uptake, if approved, will hinge on payer views of incremental value versus atezo/bev and STRIDE, and on operational practicality at community sites managing VEGF/TKI toxicities. The broader takeaway for development teams is unchanged: in rapidly evolving oncology settings, comparator selection and regional enrollment mix are not just statistical choices—they are strategic determinants of regulatory friction and time to market.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
